Fig. 2From: Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysisKaplan–Meier survival curves of patients with unresectable pancreatic cancer and a significant weight loss (> 10% bodyweight within 6 months) at diagnosis (n = 95) according to administration of pancreatic enzyme replacement therapy (PERT). The hazard ratio (HR) and 95% confidence interval (CI) associated with PERT are shown. Log-rank test (Mantel–Cox) P < 0.001Back to article page